Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huashibaidu Granule for Community-acquired Pneumonia in Children
NCT05711017Unknown
- Start
- Feb 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in community acquired pneumonia (CAP) comparing Huashibaidu Group with Placebo Group (2 arms). Primary endpoint: Change in clinical symptom score from baseline at 3 days. Status: unknown.
02
Drugs
Huashi Baidu Granule
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT05711017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05711017.